S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
TSE:BLU

BELLUS Health Stock Forecast, Price & News

C$7.67
+0.15 (+1.99%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
C$7.11
▼
C$7.77
50-Day Range
C$7.11
▼
C$9.15
52-Week Range
C$3.32
▼
C$9.47
Volume
59,549 shs
Average Volume
139,112 shs
Market Capitalization
C$600.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.


BELLUS Health logo

About BELLUS Health

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Headlines

Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?
November 26, 2021 |  finance.yahoo.com
BELLUS Health's (BLU) Buy Rating Reiterated at BTIG Research
November 16, 2021 |  americanbankingnews.com
BELLUS Health (TSE:BLU) Stock Rating Reaffirmed by HC Wainwright
November 12, 2021 |  americanbankingnews.com
BELLUS Health (TSE:BLU) Stock Price Passes Above Fifty Day Moving Average of $7.37
November 11, 2021 |  americanbankingnews.com
Bellus Health (BLU) Reports Q3 Loss
November 11, 2021 |  finance.yahoo.com
BELLUS Health (TSE:BLU) Stock Price Passes Above 50-Day Moving Average of $7.37
November 10, 2021 |  americanbankingnews.com
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
November 1, 2021 |  finance.yahoo.com
The 50% Healthcare Index Dip and a Silver Lining
October 28, 2021 |  msn.com
Bellus Health Shares Rise 11% After Completing Enrollment for Clinical Trials
September 25, 2021 |  marketwatch.com
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
September 2, 2021 |  finance.yahoo.com
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
August 23, 2021 |  finance.yahoo.com
3 Top Growth Stocks to Own Before They Take Off
July 23, 2021 |  ca.finance.yahoo.com
BELLUS Health Inc. (BLU.TO)
June 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:BLU
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.bellushealth.com
Phone
+1-450-6804500
Fax
N/A
Employees
32
Year Founded
N/A

Sales & Book Value

Annual Sales
C$16 thousand
Price / Sales
37,552.80
Cash Flow
C$0.80 per share
Price / Cash Flow
9.54
Book Value
C$1.22 per share
Price / Book
6.29

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
3.42
Quick Ratio
3.21

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
78,337,000
Free Float
N/A
Market Cap
C$600.84 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Next Earnings (Estimated)
2/24/2022

MarketRank™

Overall MarketRank™

1.58 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












BELLUS Health (TSE:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health or view top-rated stocks.

How has BELLUS Health's stock price been impacted by COVID-19 (Coronavirus)?

BELLUS Health's stock was trading at C$13.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLU stock has decreased by 41.0% and is now trading at C$7.67.
View which stocks have been most impacted by COVID-19.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BELLUS Health.

What price target have analysts set for BLU?

4 brokerages have issued 12 month price targets for BELLUS Health's stock. Their forecasts range from C$8.00 to C$14.00. On average, they expect BELLUS Health's share price to reach C$11.67 in the next year. This suggests a possible upside of 52.1% from the stock's current price.
View analysts' price targets for BELLUS Health or view top-rated stocks among Wall Street analysts.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Mr. Roberto Francesco Bellini, Pres, CEO & Director (Age 41, Pay $542.35k)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 58, Pay $221.42k)
  • Mr. Ramzi Benamar, Chief Financial Officer (Age 48, Pay $418.48k)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 64, Pay $341.13k)
  • Dr. Catherine M. Bonuccelli, Chief Medical Officer (Age 63, Pay $566.96k)
  • Mr. Daniel Matthews, Director of Investor Relations & Communications
  • Mr. Sebastien Roy, Corp. Sec. (Age 45)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 48)

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), Boeing (BA) and Walt Disney (DIS).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health?

Shares of BLU and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$7.67.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of C$600.84 million and generates C$16 thousand in revenue each year.

How many employees does BELLUS Health have?

BELLUS Health employs 32 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.